First Cathelicidin Found in Tree Frogs Kills Bacteria and Calms Inflammation

Researchers purified cathelicidin-PP from Polypedates puerensis tree frog skin and determined its amino acid sequence. They used circular dichroism spectroscopy to analyze its structure, antimicrobial assays to test its germ-killing ability, and scanning electron microscopy to visualize how it destroys bacterial membranes. Anti-inflammatory properties were tested in LPS-stimulated mouse peritoneal macrophages by measuring cytokines and nitric oxide. LPS neutralization was assessed in dose-response assays. Finally, qPCR was used to measure cathelicidin-PP expression in frog tissues after bacterial infection.

With antibiotic resistance rising globally, finding new antimicrobial compounds is urgent. Cathelicidins are especially interesting because they combine direct germ-killing with immune regulation — they fight infection on two fronts simultaneously. This discovery expands the known diversity of cathelicidins into tree frogs, a massive and largely untapped reservoir of potential drug leads. The fact that cathelicidin-PP has low toxicity to mammalian cells while retaining both antimicrobial and anti-inflammatory activity makes it a promising template for new drug development.

Amphibian skin is one of nature's richest sources of antimicrobial peptides, with over 7,600 frog species representing a vast library of potential drug candidates. Yet cathelicidins — one of the most important antimicrobial peptide families in mammals (including the human LL-37) — have been barely explored in amphibians, with only 20 identified from 10 species at the time of this study. Finding the first tree frog cathelicidin with dual antimicrobial and immunomodulatory properties extends our understanding of how this ancient peptide family has evolved across vertebrate lineages.

All experiments were conducted in vitro or ex vivo — there were no animal infection models testing whether cathelicidin-PP protects against disease in a living organism. The peptide was tested against a limited panel of microorganisms. No pharmacokinetic data (how long it lasts in the body) or toxicity studies in whole animals were performed. The clinical translatability of a frog-derived peptide to human medicine is unknown.